Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
All patients with acute coronary syndromes and without obvious bleeding or acute cerebrovascular events are candidates for heparin therapy. This article is a review of the pharmacology of unfractionated and low-molecular-weight heparins, trials of heparin therapy in acute coronary syndromes, and recommendations for using these agents.
Brener
S J
SJ
Department of Cardiology, Cleveland Clinic, USA.
D000789:Angina, Unstable / Q000188:drug therapy; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D017984:Enoxaparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin